🎗️ CDK4/6 Inhibitor (Palbociclib) Cell Cycle Simulator

Cyclin D–CDK4/6 Phosphorylates Rb to Drive G1/S Transition

Healthy cell-cycle checkpoint control before any drug is present.

• 96%: CDK4/6 kinase activity (unrestricted baseline)
• Hyperphosphorylated: Rb phosphorylation (checkpoint open)
• High: Cyclin D level (estrogen-driven)
• Free / active: E2F transcriptional state (S-genes on)

Cyclin D–CDK4/6 complex formation

Growth signals raise cyclin D, activating CDK4/6 kinase.

Rb phosphorylation opens the checkpoint

Phosphorylated Rb releases E2F, permitting S-phase entry.

Placeholder: the G1/S restriction point is the cycle's master gate.

Palbociclib Binds and Inhibits the CDK4/6 Kinase Domain

An oral CDK4/6 inhibitor competes at the kinase active site.

• CDK4/6 inhibitor: Drug class (first-in-class oral agent)
• ATP pocket: Binding site (reversible, ATP-competitive)
• 125 mg/day: Standard dose (3 weeks on, 1 off)
• ~9–11 nM: Kinase IC50 (CDK4 and CDK6)

ATP-competitive kinase inhibition

Palbociclib slots into the ATP pocket, blocking phosphotransfer.

Dose-dependent target occupancy

Higher plasma dose increases CDK4/6 occupancy and shutdown.

Placeholder: occupancy scales with dose and exposure time.

Rb Remains in Its Active, Hypophosphorylated State

Without kinase activity, Rb keeps its tumor-suppressor conformation.

• >14 sites: Rb phosphorylation sites (left unmodified)
• Hypophosphorylated: Rb functional state (active, checkpoint closed)
• High: Rb–E2F affinity (stable complex)
• Restored: Tumor-suppressor function (growth brake reapplied)

Hypophosphorylated Rb as a growth brake

Unmodified Rb folds to clamp E2F, blocking its release.

Checkpoint closure across the cell population

More cells accumulate in the active-Rb, closed-gate state.

Placeholder: Rb reactivation is the direct mechanistic outcome.

Rb Sequesters E2F, Silencing S-Phase Gene Transcription

Bound E2F cannot recruit the machinery needed for DNA replication genes.

• Sequestered: E2F1–3 targets (transcription blocked)
• Off: S-phase gene program (replication genes silent)
• Suppressed: Cyclin E/A induction (no S-phase kinases)
• Blocked: DNA replication initiation (no origin firing)

E2F as the S-phase gene switch

Free E2F normally activates replication and cyclin E/A genes.

Consequence of sustained sequestration

Silenced S-phase genes stop the replication program entirely.

Placeholder: no E2F output means no S-phase entry.

Tumor Cells Arrest in G1 — Enhanced by Hormone Therapy

Combining palbociclib with hormone therapy deepens cell-cycle arrest.

• up to ~95%: Cells in G1 arrest (at full combo dose)
• Palbociclib + AI: Typical regimen (e.g. letrozole)
• 24.8 months: PALOMA-2 median PFS (vs 14.5 mo placebo+AI)
• ER+/HER2− mBC: Indication (metastatic breast cancer)

G1 arrest halts tumor proliferation

Arrested cells stop dividing, slowing tumor growth substantially.

Hormone therapy adds upstream suppression

Lowering estrogen signaling reduces cyclin D, compounding the effect.

Placeholder: combination therapy is standard first-line ER+ mBC care.